Ocular Therapeutix Files 8-K: Other Events Reported

TL;DR

OCUL filed an 8-K for 'Other Events' on 9/30/25 - details TBD.

AI Summary

Ocular Therapeutix, Inc. filed an 8-K on September 30, 2025, reporting "Other Events." The filing does not contain specific details about the nature of these events, dollar amounts, or definitive dates beyond the filing date itself.

Why It Matters

This filing indicates that Ocular Therapeutix has reported significant events to the SEC, but the lack of detail requires further investigation to understand the implications for the company.

Risk Assessment

Risk Level: medium — The filing is an 8-K for 'Other Events' without specific details, which introduces uncertainty about the nature and impact of these events.

Key Players & Entities

• OCULAR THERAPEUTIX, INC. (company) — Filer of the 8-K report
• September 30, 2025 (date) — Date of the earliest event reported and filing date
• Delaware (jurisdiction) — State of incorporation
• 001-36554 (identifier) — SEC Commission File Number
• 15 Crosby Drive Bedford, MA 01730 (address) — Principal Executive Offices
• ( 781 ) 357-4000 (phone_number) — Company's telephone number

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value per share OCUL The Nasdaq

Filing Documents

• tm2527344d2_8k.htm (8-K) — 43KB
• 0001104659-25-094724.txt ( ) — 209KB
• ocul-20250930.xsd (EX-101.SCH) — 3KB
• ocul-20250930_lab.xml (EX-101.LAB) — 33KB
• ocul-20250930_pre.xml (EX-101.PRE) — 22KB
• tm2527344d2_8k_htm.xml (XML) — 3KB

01. Other Events

Item 8.01. Other Events. On September 30, 2025, Ocular Therapeutix, Inc., or the Company, announced certain updates regarding its development programs for AXPAXLI (also known as OTX-TKI), the Company's investigational, bioresorbable, intravitreal hydrogel incorporating axitinib, a small molecule, multi-target, tyrosine kinase inhibitor with anti-angiogenic properties. The Company is currently evaluating AXPAXLI for the treatment of wet age-related macular degeneration, or wet AMD, and plans to evaluate AXPAXLI for the treatment of non-proliferative diabetic retinopathy, or NPDR. Update on wet AMD Program SOL-1 Clinical Trial The Company is currently conducting a repeat-dosing registrational Phase 3 clinical trial, which the Company refers to as the SOL-1 trial, to assess the safety and efficacy of AXPAXLI in subjects with wet AMD. The SOL-1 trial is designed as a prospective, multi-center, double-masked, randomized (1:1), parallel-group, two-arm superiority trial comparing a single injection of AXPAXLI 450 g to a single injection of aflibercept 2 mg. The SOL-1 trial completed the randomization of 344 subjects with a diagnosis of active macular choroidal neovascularization at screening in December 2024. Under the trial protocol, subjects were eligible for enrollment in the SOL-1 trial if they were treatment-nave for wet AMD in the study eye; had central subfield thickness, or CSFT, of less than or equal to 500 microns; and had a Best Corrected Visual Acuity, or BCVA, of at least 54 letters as measured by the Early Treatment of Diabetic Retinopathy Study, or ETDRS, letters chart (approximately 20/80 Snellen equivalent vision). After screening, enrolled ETDRS letters (approximately 20/20 Snellen equivalent vision) or experiencing an improvement of at least 10 ETDRS letters with a reduction in CSFT to no greater than 350 microns

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. OCULAR THERAPEUTIX, INC. Date: September 30, 2025 By: /s/ Donald Notman Donald Notman Chief Financial Officer and Chief Operating Officer

View Full Filing

View this 8-K filing on SEC EDGAR